Racing past a wounded Juno, Kite aims to file lead CAR-T for OK by end of 2016
With Juno Therapeutics seriously delayed by a brief but painful clinical hold by the FDA, rival Kite Pharma outlined plans today to shoot for an accelerated approval after it gathers the first round of data on 50 patients from its pivotal study of a rival CAR-T, due in just a few months. And company executives say their manufacturing operations will be ready to start producing this therapy in commercial quantities before the end of this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.